News | December 01, 2009

FDA Warns Obesity Drug May Increase Cardiovascular Events

November 21, 2009 – The Food and Drug Administration (FDA) recently announced that it is reviewing data from a study suggesting patients using the drug sibutramine may have a higher number of cardiovascular events than patients using a placebo.

The FDA said the events include an increase in heart attack, stroke, resuscitated cardiac arrest and death. Sibutramine is marketed as Meridia, a prescription drug, in the United States. Meridia was approved by the FDA in 1997 for the management of obesity, including weight loss and maintenance of weight loss, in conjunction with a reduced- calorie diet. The drug is only recommended for obese patients with an initial body mass index (BMI) greater than or equal to 30 kg/m2, or BMI more than or equal to 27 kg/m2, and other risk factors such as diabetes, high cholesterol or controlled high blood pressure.

The data analysis is ongoing and the FDA is making no conclusions about the preliminary findings at this time. These findings highlight the importance of avoiding the use of sibutramine in patients with a history of coronary artery disease (heart disease), congestive heart failure, arrhythmias or stroke, as recommended in the current sibutramine labeling.

For more information: www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm191655.htm

Related Content

Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
CANTOS Study Shows Reducing Inflammation Cuts Cardiovascular Disease, Lung Cancer Risk
News | ESC| September 12, 2017
September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk b
New FOURIER Analysis Examines How Low Cholesterol Can Safely Go
News | ESC| September 12, 2017
September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressive
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies| September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
Overlay Init